Palo Alto, CA, United States of America

Claire Louise Langrish

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Claire Louise Langrish: Innovator in Antibody Development

Introduction

Claire Louise Langrish is a prominent inventor based in Palo Alto, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. Her work focuses on innovative solutions for treating inflammatory diseases.

Latest Patents

Claire Louise Langrish holds a patent for "Antibodies against human IL17 and uses thereof." This patent describes an antibody that binds to IL-17, characterized by its binding to the same IL-17 epitope as monoclonal antibody 3C1. The antibody is of human IgG1 isotype and is modified in the hinge region at amino acid positions 216-240, preferably at positions 220-240, and in the second inter-domain region at positions 327-331. This innovation has advantageous properties for the treatment of inflammatory diseases. She has 1 patent to her name.

Career Highlights

Throughout her career, Claire has worked with notable companies in the biotechnology sector, including Roche Palo Alto LLC and Roche Glycart AG. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in antibody therapies.

Collaborations

Claire has collaborated with esteemed colleagues such as Johannes Auer and Nikolaos Dimoudis. These partnerships have further enhanced her research and innovation in the field.

Conclusion

Claire Louise Langrish is a key figure in the development of therapeutic antibodies, with a focus on treating inflammatory diseases. Her innovative work and collaborations continue to impact the biotechnology industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…